News und Analysen
![The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
Shares of Novavax (NASDAQ: NVAX), a clinical-stage small-cap biotech company focused on the development of recombinant nanoparticle vaccines, surged by 25% during the month of November, according....
![2 Reasons Geron Corporation Took a Pounding in November](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
2 Reasons Geron Corporation Took a Pounding in November
Shares of Geron Corporation (NASDAQ: GERN), a clinical-stage biotech company focused on the development of oncology drugs, sank 12% during the month of November, according to data from S&P....
![The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drugmaker that had primarily grown by acquisitions and drug-price hikes in recent years, galloped higher by 43% in November, according....
![5 Key Things to Know About This Leading Marijuana Stock's Future](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
5 Key Things to Know About This Leading Marijuana Stock's Future
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of....
![Veeva Systems Inc. (VEEV) Q3 2018 Earnings Conference Call Transcript](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Veeva Systems Inc. (VEEV) Q3 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.Veeva Systems Inc. (NYSE: VEEV)Q3 2018 Earnings Conference CallDec. 5, 2017, 4:30 p.m. ETOperatorContinue readingSource: Fool.com
![3 Growth Stocks With Virtual Monopolies](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
3 Growth Stocks With Virtual Monopolies
Monopolies can be bad. Having a single company control every aspect of an entire industry is likely to lead to higher consumer prices, slower innovation, and anticompetitive behavior.Lucky for us,....
![Why Heron Therapeutics Stock Is Crashing Today](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Why Heron Therapeutics Stock Is Crashing Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average....
![Why Snap, Regal Entertainment Group, and Revance Therapeutics Jumped Today](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Why Snap, Regal Entertainment Group, and Revance Therapeutics Jumped Today
Tuesday was a down day for most of the stock market, with major benchmarks finishing with modest losses of half a percent or less. The NYSE Composite pulled back from the record highs it reached....
![Why Illumina Jumped 9.8% in November](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Why Illumina Jumped 9.8% in November
Shares of the genomic sequencing specialist Illumina (NASDAQ: ILMN) rose nearly 10% in November, according to data from S&P Global Market Intelligence. However, there wasn't any....
![Why Alexion Pharmacteuicals Sank 8.9% in November](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't....
![MEDICREA : Declaration_des_droits_de_vote_AMF_30-11-2017](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
MEDICREA : Declaration_des_droits_de_vote_AMF_30-11-2017
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
(Article L.233-8-II du Code de Commerce et Article 222-12-5 du règlement général de....
![VISIOMED GROUP lève 2,6 MEUR pour poursuivre son développement dans la santé connectée](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
VISIOMED GROUP lève 2,6 MEUR pour poursuivre son développement dans la santé connectée
Paris, le 5 décembre 2017
VISIOMED GROUP (FR0011067669 – ALVMG), société spécialisée dans l'électronique médicale nouvelle génération, annonce la réalisation d'une augmentation de 2,6 M€ qui....
![Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
Shares of specialty pharmaceutical developer Collegium Pharmaceutical (NASDAQ: COLL) rose over 23% today after the company announced that it will acquire the pain drug Nucynta from Depomed....
![Why Revance Therapeutics Is Soaring Today](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Why Revance Therapeutics Is Soaring Today
In response to the company's strong results from two pivotal phase 3 trials, shares of Revance Therapeutics (NASDAQ: RVNC), a clinical-stage biotech focused on aesthetics, rose 36% as of 11:10....
![MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada
Der MorphoSys-Lizenzpartner Janssen hat in Kanada die Zulassung zur Behandlung erwachsener Patienten mit moderater bis schwerer Form von Schuppenflechte mit dem Medikament Tremfya erhalten. Das....
![Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November
After the company updated the timeline for filing its pain-relieving drug for approval from the Food and Drug Administration, and presented early-stage study results for its solid-tumor cancer....
![3 Things Veeva Systems Inc. Shareholders Should Watch Going Into Earnings](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
3 Things Veeva Systems Inc. Shareholders Should Watch Going Into Earnings
Veeva Systems (NYSE: VEEV), which provides cloud solutions primarily to pharmaceutical companies, will be reporting earnings next week. While the stock has been a resounding success over the past....
![What Happened in the Stock Market Today](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
What Happened in the Stock Market Today
Stocks began the day in positive territory thanks to optimism over the Senate's passage of a tax bill, but declined over the length of the session, ultimately ending with mixed results. The Dow....
![Why Ra Pharmaceuticals, Inc. Got Hammered Today](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Why Ra Pharmaceuticals, Inc. Got Hammered Today
Ra Pharmaceuticals (NASDAQ: RARX) characterized its interim phase 2 data testing RA101495 SC in patients with paroxysmal nocturnal hemoglobinuria (PNH) as "positive," but the market sees it....
![Why Endocyte, Inc. Stock Briefly Spiked Today](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Why Endocyte, Inc. Stock Briefly Spiked Today
Shares of the clinical-stage biotech Endocyte (NASDAQ: ECYT) briefly rose by as much as 16% Monday on more than double the average daily volume. The catalyst? Investors appear to have noticed a....
![1 High-Risk Penny Stock That May Be Worth Buying](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
1 High-Risk Penny Stock That May Be Worth Buying
Penny stocks, or stocks with a sub-$5 share price, generally aren't my cup of tea. These types of companies tend to be far too risky to make them worthy of serious investment consideration. The....
![BASTIDE : Déclaration du nombre d'actions et de droits de vote au 30.11.2017](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
BASTIDE : Déclaration du nombre d'actions et de droits de vote au 30.11.2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
![3 Stocks That Quadrupled](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
3 Stocks That Quadrupled
The stock market continues to put on a clinic about how to stomp all over expectations. The Dow Jones Industrial Average is up 25% this year and the S&P 500 is 20% higher, but stack them up....
![Where Will Exact Sciences Corporation Be in 5 Years?](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Where Will Exact Sciences Corporation Be in 5 Years?
Roughly 18 months ago, Exact Sciences (NASDAQ: EXAS) was in rough shape. Cash was getting tight as the company spent aggressively to commercialize its new colon cancer test. Add in some troubling....
![3 Reasons Pfizer Should Buy Celgene in 2018](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
3 Reasons Pfizer Should Buy Celgene in 2018
You might think it's a crazy idea. Maybe it is a crazy idea. But sometimes crazy ideas are the ones that wind up being the best. So here it is: Pfizer (NYSE: PFE) should buy Celgene (NASDAQ: CELG)....